One-year clinical outcomes among patients with metabolic syndrome and acute myocardial infarction

Mi Seon Ji, Myung Ho Jeong, Youngkeun Ahn, Young Jo Kim, Shung Chull Chae, Taek Jong Hong, In Whan Seong, Jei Keon Chae, Chong Jin Kim, Myeong Chan Cho, Seung-Woon Rha, Jang Ho Bae, Ki Bae Seung, Seung Jung Park

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Background and Objectives: Metabolic syndrome (MetS) is an important risk factor for cardiovascular disease. However, the clinical outcome of acute myocardial infarction (AMI) with MetS has not been well examined. The purpose of this study was to evaluate the clinical outcomes of AMI patients with MetS. Subjects and Methods: We evaluated a total of 6352 AMI patients who had successful percutaneous coronary interventions and could be identified for MetS between 2005 and 2008 at 51 hospitals participating in the Korea Acute Myocardial Infarction Registry. They were divided into 2 groups according to the presence of MetS: the MetS group (n=2493, 39.2%) versus the Non-MetS group (n=3859, 60.8%). In addition, 4049 AMI patients with high levels of low density lipoprotein-cholesterol (LDL-C) (≥100 mg/dL) among them, were divided into the MetS group (n=1561, 38.6%) versus the Non-MetS group (n=2488, 61.4%). Results: In the overall population, there was no significant difference in 12-month the major adverse cardiac events (MACE) rate between the 2 groups. However, the MetS group showed a significantly higher 12-month MACE rate in the high LDL-C population. Multivariate analysis showed that MetS was an independent prognostic factor for 12-month MACE {hazard ratio (HR) 1.607, 95% confidence interval (CI) 1.027 to 2.513, adjusted p=0.038} and for 12-month target vessel revascularization (HR 1.564, 95% CI 1.092 to 2.240, adjusted p=0.015) in the high LDL-C population. Conclusion: MetS patients with AMI in the overall population showed no significant difference in 12-month clinical outcomes. However, in patients with higher LDL-C ≥100 mg/dL, they showed significantly worse clinical outcome than Non-MetS patients. Therefore, it is important to ascertain the presence of MetS in AMI patients, and more aggressive therapy should be strongly considered for AMI patient with MetS.

Original languageEnglish
Pages (from-to)519-526
Number of pages8
JournalKorean Circulation Journal
Volume43
Issue number8
DOIs
Publication statusPublished - 2013 Aug 1

Fingerprint

Myocardial Infarction
LDL Cholesterol
HDL Cholesterol
Population
Confidence Intervals
Percutaneous Coronary Intervention
Korea
Registries
Cardiovascular Diseases
Multivariate Analysis

Keywords

  • Low density lipoprotein- cholesterol
  • Metabolic syndrome
  • Myocardial infarction

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Internal Medicine

Cite this

Ji, M. S., Jeong, M. H., Ahn, Y., Kim, Y. J., Chae, S. C., Hong, T. J., ... Park, S. J. (2013). One-year clinical outcomes among patients with metabolic syndrome and acute myocardial infarction. Korean Circulation Journal, 43(8), 519-526. https://doi.org/10.4070/kcj.2013.43.8.519

One-year clinical outcomes among patients with metabolic syndrome and acute myocardial infarction. / Ji, Mi Seon; Jeong, Myung Ho; Ahn, Youngkeun; Kim, Young Jo; Chae, Shung Chull; Hong, Taek Jong; Seong, In Whan; Chae, Jei Keon; Kim, Chong Jin; Cho, Myeong Chan; Rha, Seung-Woon; Bae, Jang Ho; Seung, Ki Bae; Park, Seung Jung.

In: Korean Circulation Journal, Vol. 43, No. 8, 01.08.2013, p. 519-526.

Research output: Contribution to journalArticle

Ji, MS, Jeong, MH, Ahn, Y, Kim, YJ, Chae, SC, Hong, TJ, Seong, IW, Chae, JK, Kim, CJ, Cho, MC, Rha, S-W, Bae, JH, Seung, KB & Park, SJ 2013, 'One-year clinical outcomes among patients with metabolic syndrome and acute myocardial infarction', Korean Circulation Journal, vol. 43, no. 8, pp. 519-526. https://doi.org/10.4070/kcj.2013.43.8.519
Ji, Mi Seon ; Jeong, Myung Ho ; Ahn, Youngkeun ; Kim, Young Jo ; Chae, Shung Chull ; Hong, Taek Jong ; Seong, In Whan ; Chae, Jei Keon ; Kim, Chong Jin ; Cho, Myeong Chan ; Rha, Seung-Woon ; Bae, Jang Ho ; Seung, Ki Bae ; Park, Seung Jung. / One-year clinical outcomes among patients with metabolic syndrome and acute myocardial infarction. In: Korean Circulation Journal. 2013 ; Vol. 43, No. 8. pp. 519-526.
@article{6aa02af9eca345e5ae8de04ec8e5513b,
title = "One-year clinical outcomes among patients with metabolic syndrome and acute myocardial infarction",
abstract = "Background and Objectives: Metabolic syndrome (MetS) is an important risk factor for cardiovascular disease. However, the clinical outcome of acute myocardial infarction (AMI) with MetS has not been well examined. The purpose of this study was to evaluate the clinical outcomes of AMI patients with MetS. Subjects and Methods: We evaluated a total of 6352 AMI patients who had successful percutaneous coronary interventions and could be identified for MetS between 2005 and 2008 at 51 hospitals participating in the Korea Acute Myocardial Infarction Registry. They were divided into 2 groups according to the presence of MetS: the MetS group (n=2493, 39.2{\%}) versus the Non-MetS group (n=3859, 60.8{\%}). In addition, 4049 AMI patients with high levels of low density lipoprotein-cholesterol (LDL-C) (≥100 mg/dL) among them, were divided into the MetS group (n=1561, 38.6{\%}) versus the Non-MetS group (n=2488, 61.4{\%}). Results: In the overall population, there was no significant difference in 12-month the major adverse cardiac events (MACE) rate between the 2 groups. However, the MetS group showed a significantly higher 12-month MACE rate in the high LDL-C population. Multivariate analysis showed that MetS was an independent prognostic factor for 12-month MACE {hazard ratio (HR) 1.607, 95{\%} confidence interval (CI) 1.027 to 2.513, adjusted p=0.038} and for 12-month target vessel revascularization (HR 1.564, 95{\%} CI 1.092 to 2.240, adjusted p=0.015) in the high LDL-C population. Conclusion: MetS patients with AMI in the overall population showed no significant difference in 12-month clinical outcomes. However, in patients with higher LDL-C ≥100 mg/dL, they showed significantly worse clinical outcome than Non-MetS patients. Therefore, it is important to ascertain the presence of MetS in AMI patients, and more aggressive therapy should be strongly considered for AMI patient with MetS.",
keywords = "Low density lipoprotein- cholesterol, Metabolic syndrome, Myocardial infarction",
author = "Ji, {Mi Seon} and Jeong, {Myung Ho} and Youngkeun Ahn and Kim, {Young Jo} and Chae, {Shung Chull} and Hong, {Taek Jong} and Seong, {In Whan} and Chae, {Jei Keon} and Kim, {Chong Jin} and Cho, {Myeong Chan} and Seung-Woon Rha and Bae, {Jang Ho} and Seung, {Ki Bae} and Park, {Seung Jung}",
year = "2013",
month = "8",
day = "1",
doi = "10.4070/kcj.2013.43.8.519",
language = "English",
volume = "43",
pages = "519--526",
journal = "Korean Circulation Journal",
issn = "1738-5520",
publisher = "Korean Society of Circulation",
number = "8",

}

TY - JOUR

T1 - One-year clinical outcomes among patients with metabolic syndrome and acute myocardial infarction

AU - Ji, Mi Seon

AU - Jeong, Myung Ho

AU - Ahn, Youngkeun

AU - Kim, Young Jo

AU - Chae, Shung Chull

AU - Hong, Taek Jong

AU - Seong, In Whan

AU - Chae, Jei Keon

AU - Kim, Chong Jin

AU - Cho, Myeong Chan

AU - Rha, Seung-Woon

AU - Bae, Jang Ho

AU - Seung, Ki Bae

AU - Park, Seung Jung

PY - 2013/8/1

Y1 - 2013/8/1

N2 - Background and Objectives: Metabolic syndrome (MetS) is an important risk factor for cardiovascular disease. However, the clinical outcome of acute myocardial infarction (AMI) with MetS has not been well examined. The purpose of this study was to evaluate the clinical outcomes of AMI patients with MetS. Subjects and Methods: We evaluated a total of 6352 AMI patients who had successful percutaneous coronary interventions and could be identified for MetS between 2005 and 2008 at 51 hospitals participating in the Korea Acute Myocardial Infarction Registry. They were divided into 2 groups according to the presence of MetS: the MetS group (n=2493, 39.2%) versus the Non-MetS group (n=3859, 60.8%). In addition, 4049 AMI patients with high levels of low density lipoprotein-cholesterol (LDL-C) (≥100 mg/dL) among them, were divided into the MetS group (n=1561, 38.6%) versus the Non-MetS group (n=2488, 61.4%). Results: In the overall population, there was no significant difference in 12-month the major adverse cardiac events (MACE) rate between the 2 groups. However, the MetS group showed a significantly higher 12-month MACE rate in the high LDL-C population. Multivariate analysis showed that MetS was an independent prognostic factor for 12-month MACE {hazard ratio (HR) 1.607, 95% confidence interval (CI) 1.027 to 2.513, adjusted p=0.038} and for 12-month target vessel revascularization (HR 1.564, 95% CI 1.092 to 2.240, adjusted p=0.015) in the high LDL-C population. Conclusion: MetS patients with AMI in the overall population showed no significant difference in 12-month clinical outcomes. However, in patients with higher LDL-C ≥100 mg/dL, they showed significantly worse clinical outcome than Non-MetS patients. Therefore, it is important to ascertain the presence of MetS in AMI patients, and more aggressive therapy should be strongly considered for AMI patient with MetS.

AB - Background and Objectives: Metabolic syndrome (MetS) is an important risk factor for cardiovascular disease. However, the clinical outcome of acute myocardial infarction (AMI) with MetS has not been well examined. The purpose of this study was to evaluate the clinical outcomes of AMI patients with MetS. Subjects and Methods: We evaluated a total of 6352 AMI patients who had successful percutaneous coronary interventions and could be identified for MetS between 2005 and 2008 at 51 hospitals participating in the Korea Acute Myocardial Infarction Registry. They were divided into 2 groups according to the presence of MetS: the MetS group (n=2493, 39.2%) versus the Non-MetS group (n=3859, 60.8%). In addition, 4049 AMI patients with high levels of low density lipoprotein-cholesterol (LDL-C) (≥100 mg/dL) among them, were divided into the MetS group (n=1561, 38.6%) versus the Non-MetS group (n=2488, 61.4%). Results: In the overall population, there was no significant difference in 12-month the major adverse cardiac events (MACE) rate between the 2 groups. However, the MetS group showed a significantly higher 12-month MACE rate in the high LDL-C population. Multivariate analysis showed that MetS was an independent prognostic factor for 12-month MACE {hazard ratio (HR) 1.607, 95% confidence interval (CI) 1.027 to 2.513, adjusted p=0.038} and for 12-month target vessel revascularization (HR 1.564, 95% CI 1.092 to 2.240, adjusted p=0.015) in the high LDL-C population. Conclusion: MetS patients with AMI in the overall population showed no significant difference in 12-month clinical outcomes. However, in patients with higher LDL-C ≥100 mg/dL, they showed significantly worse clinical outcome than Non-MetS patients. Therefore, it is important to ascertain the presence of MetS in AMI patients, and more aggressive therapy should be strongly considered for AMI patient with MetS.

KW - Low density lipoprotein- cholesterol

KW - Metabolic syndrome

KW - Myocardial infarction

UR - http://www.scopus.com/inward/record.url?scp=84885460063&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885460063&partnerID=8YFLogxK

U2 - 10.4070/kcj.2013.43.8.519

DO - 10.4070/kcj.2013.43.8.519

M3 - Article

C2 - 24044010

AN - SCOPUS:84885460063

VL - 43

SP - 519

EP - 526

JO - Korean Circulation Journal

JF - Korean Circulation Journal

SN - 1738-5520

IS - 8

ER -